PRAHA VACCINES

Kutna Hora, Czechia Founded: 2017 • Age: 9 yrs Acquired By Novavax
Serums and vaccines are developed and produced by PRAHA VACCINES.
Annual revenue $8.3M Latest available
Total funding - Funding intelligence
Employees 4148 Tracked headcount
Investors 1 Known backers
Products - Services tracked
Competitors 10 Brand Intelligence

About PRAHA VACCINES

PRAHA VACCINES is a company based in Kutna Hora (Czechia) founded in 2017 was acquired by Novavax in May 2020. The company has 4,148 employees as of December 31, 2021. PRAHA VACCINES operates in a competitive market with competitors including Neovacs, Intravacc, Fina Biosolutions, Yapanbio and VERAXA, among others.

  • Headquarter Kutna Hora, Czechia
  • Employees 4148 as on 31 Dec, 2021
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Legal Name Active 24, S.R.O.
Operational Areas
Healthcare → Healthcare Services & Infrastructure Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    $8.29 M (USD)
    5
    as on Dec 31, 2022
  • Net Profit
    $302.32 K (USD)
    90
    as on Dec 31, 2022
  • EBITDA
    $1.6 M (USD)
    44
    as on Dec 31, 2022
  • Latest Funding Round
    Not available
  • Investors
  • Employee Count
    4148

    as on Dec 31, 2021

  • Acquired by
    Novavax

    (May 27, 2020)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of PRAHA VACCINES

Premium access

Detailed funding history for PRAHA VACCINES

Round names, dates, amounts, investors, and valuation history require an active premium plan.

  • Round names and dates
  • Funding amounts
  • Participating investors
  • Valuation history

Verified entity values are shown only after access is granted.

Investors in PRAHA VACCINES

PRAHA VACCINES has secured backing from 1 investor. Prominent investors backing the company include Novavax.

All
Investor Description Founded Year Domain Location
Novel vaccines are developed using nanoparticle and matrix adjuvant technology.
Locked Locked Locked
Premium access

Investor details for PRAHA VACCINES

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by PRAHA VACCINES

Investments
Premium access

Investment portfolio details for PRAHA VACCINES

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - PRAHA VACCINES

Premium access

Detailed financials for PRAHA VACCINES

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Praha Vaccines Comparisons

PRAHA VACCINES Primary company
Description
Serums and vaccines are developed and produced by PRAHA VACC...
Location
Kutna Hora, Czechia
Founded Year
2017
Annual Revenue
$8.29 M (USD)
Net Profit
$302.32 K (USD)
EBITDA
$1.6 M (USD)
Employees
4,148
As of 2021
Premium access

Peer comparison for PRAHA VACCINES

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of PRAHA VACCINES

PRAHA VACCINES operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Neovacs, Intravacc, Fina Biosolutions, Yapanbio and VERAXA, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Vaccine manufacturing services are provided by Neovacs CDMO.
Locked Locked Locked
Vaccine development services for bacterial and viral vaccines are provided.
Locked Locked Locked
Biotechnology company specializing in bioconjugation services mainly for vaccine development
Locked Locked Locked
Contract manufacturing of bio-therapeutics and vaccines is provided.
Locked Locked Locked
Antibody therapeutics for cancer treatment are developed via microfluidic screening.
Locked Locked Locked
New molecules are discovered, developed, and manufactured in biotechnology.
Premium access

Detailed competitors of PRAHA VACCINES

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Praha Vaccines

Premium access

Complete news archive for PRAHA VACCINES

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about PRAHA VACCINES

PRAHA VACCINES was founded in 2017.

PRAHA VACCINES is headquartered in Kutna Hora, Czechia. It is registered at Kutna Hora, Central Bohemian Region, Czechia.

As of Dec 31, 2021, the latest employee count at PRAHA VACCINES is 4,148.

Annual revenue of PRAHA VACCINES is $8.29M as on Dec 31, 2022.

PRAHA VACCINES was established in 2017 in Kutna Hora, Czech Republic. Operations are centered on the development and production of serums and vaccines within the biotechnology and pharmaceutical sectors. Research activities are conducted to support vaccine manufacturing, with a focus on serum-based solutions. The companys domain, prahavaccines.cz, facilitates information dissemination. Geographic operations remain based in the Czech Republic, serving regional and potential international needs.

PRAHA VACCINES's top competitors include Neovacs, Yapanbio and VERAXA.

PRAHA VACCINES has 1 investor. Key investors include Novavax.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available